

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>OMENN GILBERT S</u>  (Last) (First) (Middle) <u>C/O ANGION BIOMEDICA CORP.</u> <u>51 CHARLES LINDBERGH BLVD.</u>  (Street) <u>UNIONDALE NY 11553</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Angion Biomedica Corp. [ ANGN ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/09/2021</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/09/2021		C		23,483	A	\$11.57	42,152	I	Trust <sup>(1)</sup>
Common Stock	02/09/2021		C		23,391	A	\$11.57	65,543	I	Trust <sup>(1)</sup>
Common Stock	02/09/2021		C		14,783	A	\$11.57	80,326	I	Trust <sup>(1)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Convertible Promissory Note	\$16	02/09/2021		C			\$271,698.64	(2)	(3)	Common Stock	\$271,698.64	\$0.00	0	I	Trust <sup>(1)</sup>
Convertible Promissory Note	\$16	02/09/2021		C			\$270,630.14	(2)	(4)	Common Stock	\$270,630.14	\$0.00	0	I	Trust <sup>(1)</sup>
Convertible Promissory Note	\$16	02/09/2021		C			\$171,046.24	(2)	(5)	Common Stock	\$171,046.24	\$0.00	0	I	Trust <sup>(1)</sup>

**Explanation of Responses:**

- Gilbert S. Omenn Revocable Trust.
- The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.
- The convertible promissory note ("Convertible Note") had a maturity date of May 20, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to \$18.00 per Common Share.
- The convertible promissory note ("Convertible Note") had a maturity date of June 1, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to \$18.00 per Common Share.
- The convertible promissory note ("Convertible Note") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to \$18.00 per Common Share.

/s/ Jennifer J. Rhodes, as  
attorney-in fact for Gilbert S. Omenn      02/11/2021

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.